Abstract:Peng Wang, Guilian Kong Department of Nuclear Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 450003, People's Republic of China Correspondence: Guilian Kong, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 450003, People's Republic of China, Email Background: Angiogenesis and ferroptosis are both linked to hepatocellular carcinoma (HCC) development, recurrence, and medication resistance. As a result, a thorough examination of the link between genes associated with angiogenesis and ferroptosis and immunotherapy efficacy is required to improve the dismal prognosis of HCC patients. Methods: The molecular subtypes were found using a non-negative matrix factorization technique (NMF) based on the genes associated with angiogenesis and ferroptosis. Based on the differentially expressed genes (DEGs) screed between different molecular subtypes, an angiogenesis and ferroptosis-related prognostic stratification model was built using LASSO-COX regression, random forest technique, and extreme gradient boosting (XGBoost), which was further validated in the ICGC and GSE14520 databases. The impact of this model on tumor microenvironment (TME) and immunotherapy sensitivity was also investigated. The expression levels of candidate genes were detected and validated by Real-Time PCR and immunohistochemistry between liver cancer tissues and adjacent non-tumor liver tissues. Results: Both angiogenesis and ferroptosis-related genes can significantly divide HCC patients into two subgroups with different survival outcomes, mutation profiles, and immune microenvironments. We screened six core genes (SLC10A1, PAEP, DPYSL4, MSC, NQO1, and CD24) for the construction of prognostic models by three machine learning methods after intersecting DEGs between angiogenesis and ferroptosis-related subgroups. In both the TCGA, ICGC, and GSE14520 datasets, the model exhibits high prediction efficiency based on the analysis of KM survival curves and ROC curves. Immunomodulatory genes analysis suggested that the model could be used to predict which patients are most likely to benefit from immunotherapy. Furthermore, the transcriptional expression levels of SLC10A1 in the validation experiment matched the outcomes derived from public datasets. Conclusions: We identified a new angiogenesis and ferroptosis-related signature that might offer the molecular characteristic information needed for an efficient prognostic assessment and perhaps tailored treatment for HCC patients. Keywords: HCC, angiogenesis, ferroptosis, prognosis, immunotherapy Ferroptosis is a novel form of iron-dependent cell death characterized by impaired intracellular lipid oxide metabolism due to the accumulation of unsaturated fatty acids and lipid reactive oxygen species (ROS) on the cell membrane. 1 In recent years, an increasing number of studies have found that ferroptosis plays an essential role in tumorigenesis, especially in hepatocellular carcinoma (HCC). 2,3 Cancer cells undergoing ferroptosis may suppress the body's anti-tumor immunity and promote tumor growth by releasing some of the signaling substances such as oxidized lipid mediators. 4,5 Many molecules could modulate the susceptibility of cells to ferroptosis in terms of lipid metabolism, such as Glutathione peroxidase 4 (GPX4). 6 Inactivation of GPX4 was associated with increased sensitivity to ferroptosis, which significantly inhibited the development of HCC. 7 Furthermore, anti-PD-1 immunotherapy-activated CD8 + T cells could enhance ferroptosis in tumor cells by releasing interferon-gamma (IFN-γ) and further improve immune potency without harming normal cells. 8 The above indicated that further exploration of the ferroptosis mechanism will contribute to the development of new therapeutic strategies for HCC. Angiogenesis is a common process in solid tumors, contributing significantly to tumor development, infiltration, and vascular anomalies by giving the tumor tissue oxygen and nutrients for metabolism. 9 Inhibition of tumor angiogenesis has become the key to modern tumor therapy, and therapies that normalize blood vessels have been approved for first-line treatment. For anti-angiogenesis treatment in advanced HCC, sorafenib and several additional angiogenesis inhibitors (also known as tyrosine kinase inhibitors, or TKIs) have been employed. 10,11 Finding biomarkers of therapy response, however, will aid in the development of individualized treatment plans and enhance patient outcomes as treatment response varies from person to person. The fact that Evodiam -Abstract Truncated-

A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome

Screening and Identification of Angiogenesis-Related Genes As Potential Novel Prognostic Biomarkers of Hepatocellular Carcinoma Through Bioinformatics Analysis.

An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma

Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma

Angiogenesis-Related Immune Signatures Correlate With Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity in Hepatocellular Carcinoma

Establishment and validation of a cholesterol metabolism-related prognostic signature for hepatocellular carcinoma

Prognostic Hypoxia-Angiogenesis-Related Gene Signature in Hepatocellular Carcinoma, in Which HILPDA Contributes to Tumor Progression

Hypoxia-Related Immune Gene Signature Predicting Prognosis in Patients With Hepatocellular Carcinoma

An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma

Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients

A novel immune-related gene signature predicts the prognosis of hepatocellular carcinoma

Nomogram for Prediction of Hepatocellular Carcinoma Prognosis

Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis

Development of a Prognostic Signature Based on Anoikis-Related Genes in Hepatocellular Carcinoma with the Utilization of LASSO-cox Method

Prognostic role of expression of angiogenesis markers in hepatocellular carcinoma: A bioinformatics analysis

A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors

A Novel PI3K/AKT Signaling Pathway- Associated Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma

Identification of VEGFs-related gene signature for predicting microangiogenesis and hepatocellular carcinoma prognosis

Development of a Novel CD8+ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma

Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome

Comprehensive Analysis of Angiogenesis and Ferroptosis Genes for Predicting the Survival Outcome and Immunotherapy Response of Hepatocellular Carcinoma